Atlas Trials

Chronic Phase-Chronic Myeloid Leukemia

11 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Chronic Phase-Chronic Myeloid Leukemia

RecordFirmDate
Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients (NCT04793399)Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica2021-02-24
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors (NCT03934372)Incyte Biosciences International Sàrl2020-01-29
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors (NCT03610971)H. Lee Moffitt Cancer Center and Research Institute2019-11-19
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States (NCT03045120)Bristol-Myers Squibb2017-07-19
A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia (NCT02627677)Ariad Pharmaceuticals2015-12-31
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response (NCT01850004)Bristol-Myers Squibb2014-01-22
Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response (NCT01933906)Arbeitsgemeinschaft medikamentoese Tumortherapie2013-08-30
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia (NCT01914484)University Health Network, Toronto2013-08-01
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients (NCT01702064)H. Lee Moffitt Cancer Center and Research Institute2013-02-21
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib (NCT01660906)Bristol-Myers Squibb2012-12-01
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (NCT01593254)Bristol-Myers Squibb2012-09-12

Track Chronic Phase-Chronic Myeloid Leukemia automatically

Every clearance here is in the API, with alerts when new ones post.